Vivoryon Therapeutics N.V. (VVY.AS)
EUR 1.97
(0.71%)
EUR 1.97
(0.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -28.83 Million EUR | -0.69% |
| 2022 | -29.13 Million EUR | -127.49% |
| 2021 | -12.8 Million EUR | 20.05% |
| 2020 | -16.01 Million EUR | -106.03% |
| 2019 | -7.77 Million EUR | -0.61% |
| 2018 | -7.72 Million EUR | 22.46% |
| 2017 | -9.96 Million EUR | 28.1% |
| 2016 | -13.86 Million EUR | -3.15% |
| 2015 | -13.43 Million EUR | -19.26% |
| 2014 | -11.26 Million EUR | -16.74% |
| 2013 | -9.65 Million EUR | 8.59% |
| 2012 | -10.55 Million EUR | 26.01% |
| 2011 | -14.26 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -13.8 Million EUR | 0.0% |
| 2023 FY | -29.33 Million EUR | -0.69% |
| 2023 Q2 | -10.69 Million EUR | 0.0% |
| 2023 Q4 | -17.54 Million EUR | 0.0% |
| 2022 Q4 | -15.75 Million EUR | 0.0% |
| 2022 FY | -29.13 Million EUR | -127.49% |
| 2022 Q2 | -13.37 Million EUR | 0.0% |
| 2021 Q4 | -1.01 Million EUR | 0.0% |
| 2021 Q2 | -11.79 Million EUR | 0.0% |
| 2021 FY | -12.8 Million EUR | 20.05% |
| 2020 Q4 | -8.49 Million EUR | 0.0% |
| 2020 FY | -16.01 Million EUR | -106.03% |
| 2020 Q2 | -7.51 Million EUR | 0.0% |
| 2019 Q4 | -4.68 Million EUR | 0.0% |
| 2019 Q2 | -3.08 Million EUR | 0.0% |
| 2019 FY | -7.77 Million EUR | -0.61% |
| 2018 Q2 | -4.13 Million EUR | 0.0% |
| 2018 FY | -7.72 Million EUR | 22.46% |
| 2018 Q4 | -3.56 Million EUR | 0.0% |
| 2017 Q2 | -6.26 Million EUR | 0.0% |
| 2017 FY | -9.96 Million EUR | 28.1% |
| 2017 Q4 | -3.69 Million EUR | 0.0% |
| 2016 Q4 | -7.78 Million EUR | 0.0% |
| 2016 FY | -13.86 Million EUR | -3.15% |
| 2016 Q2 | -5.98 Million EUR | 0.0% |
| 2015 Q4 | -7.21 Million EUR | 0.0% |
| 2015 FY | -13.43 Million EUR | -19.26% |
| 2015 Q2 | -6.17 Million EUR | 0.0% |
| 2014 Q4 | -7.52 Million EUR | 0.0% |
| 2014 FY | -11.26 Million EUR | -16.74% |
| 2014 Q2 | -3.73 Million EUR | 0.0% |
| 2013 Q4 | -4.88 Million EUR | -99.23% |
| 2013 Q3 | -2.45 Million EUR | 48.49% |
| 2013 Q2 | -4.76 Million EUR | -94.13% |
| 2013 FY | -9.65 Million EUR | 8.59% |
| 2013 Q1 | -2.45 Million EUR | 0.0% |
| 2012 Q2 | -4.43 Million EUR | 0.0% |
| 2012 Q3 | -4.43 Million EUR | 0.0% |
| 2012 Q4 | -2.45 Million EUR | 44.63% |
| 2012 FY | -10.55 Million EUR | 26.01% |
| 2012 Q1 | -4.43 Million EUR | 0.0% |
| 2011 Q3 | -4.06 Million EUR | 0.0% |
| 2011 Q4 | -4.43 Million EUR | -9.12% |
| 2011 Q2 | -4.06 Million EUR | 0.0% |
| 2011 Q1 | -4.06 Million EUR | 0.0% |
| 2011 FY | -14.26 Million EUR | 0.0% |
| 2010 Q4 | -4.06 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -745.164% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 77.361% |
| Adocia SA | -17.62 Million EUR | -63.642% |
| Aelis Farma SA | -6.46 Million EUR | -346.324% |
| Biophytis S.A. | -14.33 Million EUR | -101.193% |
| Advicenne S.A. | -6.45 Million EUR | -346.601% |
| genOway Société anonyme | 2.06 Million EUR | 1496.265% |
| IntegraGen SA | -183.77 Thousand EUR | -15591.897% |
| Medesis Pharma S.A. | -4.22 Million EUR | -581.832% |
| Neovacs S.A. | -6.9 Million EUR | -317.471% |
| NFL Biosciences SA | -4.43 Million EUR | -550.886% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -3605.426% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -819.18% |
| Sensorion SA | -22.31 Million EUR | -29.252% |
| Theranexus Société Anonyme | -7.64 Million EUR | -277.266% |
| TME Pharma N.V. | -5.62 Million EUR | -412.749% |
| Valbiotis SA | -7.16 Million EUR | -302.751% |
| TheraVet SA | -2.17 Million EUR | -1225.773% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -42.138% |
| argenx SE | -417.15 Million EUR | 93.087% |
| BioSenic S.A. | -7.04 Million EUR | -309.616% |
| Celyad Oncology SA | -8.45 Million EUR | -240.984% |
| DBV Technologies S.A. | -85.24 Million EUR | 66.172% |
| Galapagos NV | -88.26 Million EUR | 67.328% |
| Genfit S.A. | -26.58 Million EUR | -8.491% |
| GeNeuro SA | -14.35 Million EUR | -100.853% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -80.31% |
| Innate Pharma S.A. | -12.66 Million EUR | -127.619% |
| Inventiva S.A. | -102.7 Million EUR | 71.924% |
| MaaT Pharma SA | -19.94 Million EUR | -44.597% |
| MedinCell S.A. | -20.97 Million EUR | -37.47% |
| Nanobiotix S.A. | -26.77 Million EUR | -7.685% |
| Onward Medical N.V. | -35.46 Million EUR | 18.684% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -533.893% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -25.455% |
| Oxurion NV | -12.11 Million EUR | -138.126% |
| Pharming Group N.V. | -4.87 Million EUR | -490.977% |
| Poxel S.A. | -28.76 Million EUR | -0.254% |
| GenSight Biologics S.A. | -29.69 Million EUR | 2.893% |
| Transgene SA | -30.01 Million EUR | 3.915% |
| Financière de Tubize SA | -2.14 Million EUR | -1245.026% |
| UCB SA | 604 Million EUR | 104.774% |
| Valneva SE | -82.08 Million EUR | 64.87% |